June 8, 2020 / 1:42 PM / a month ago

BRIEF-Axovant Completes Enrollment Of Low-Dose Cohort In Phase 1/2 Study Of AXO-AAV-GM1, Expands Study

June 8 (Reuters) - Axovant Gene Therapies Ltd:

* AXOVANT COMPLETES ENROLLMENT OF LOW-DOSE COHORT IN PHASE 1/2 STUDY OF AXO-AAV-GM1 AND EXPANDS STUDY TO INCLUDE TYPE I (INFANTILE ONSET) PATIENTS WITH GM1 GANGLIOSIDOSIS

* AXOVANT GENE THERAPIES LTD - SIX-MONTH DATA FROM LOW-DOSE COHORT OF AXO-AAV-GM1 EXPECTED IN Q4 2020

* AXOVANT GENE THERAPIES LTD - EXPECT TO INITIATE HIGH-DOSE COHORT OF AXO-AAV-GM1 IN 2H 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below